$NUKK
Nukkleus Inc. Stock $nukk

$nukk Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023088733 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$5.242M	$0.00
YoY Change
Cost Of Revenue	$4.784M
YoY Change	-11.92%
Gross Profit	$458.7K
YoY Change	-935.98%
Gross Profit Margin	8.75%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$9.406M	$116.7K
YoY Change	8635.89%	-75.74%
Operating Profit	-$8.947M	-$116.7K
YoY Change	5404.63%	-75.74%
Interest Expense	$7.422K	-$9.390K
YoY Change	-96.54%	-90.41%
% of Operating Profit
Other Income/Expense, Net	$19.13K	-$9.394K
YoY Change	644.51%	-90.4%
Pretax Income	-$8.928M	-$126.1K
YoY Change	-8446.35%	-78.22%
Income Tax
% Of Pretax Income
Net Earnings	-$8.928M	-$126.1K
YoY Change	-8446.27%	-78.22%
Net Earnings / Revenue	-170.3%
Basic Earnings Per Share	-$0.85	-$0.07
Diluted Earnings Per Share	-$0.85	-$0.07
COMMON SHARES
Basic Shares Outstanding	1.815M shares	1.815M shares
Diluted Shares Outstanding	10.56M shares	1.914M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$4.608M
YoY Change		-85.23%
Cash & Equivalents	$204.1K	$4.608M
Short-Term Investments
Other Short-Term Assets	$32.93K	$32.52K
YoY Change	4349.59%	-37.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$29.49K	$2.039M
Total Short-Term Assets	$1.960M	$4.608M
YoY Change	-67.93%	-85.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$391.2K	$391.2K
YoY Change	-94.07%	-94.07%
Other Assets
YoY Change
Total Long-Term Assets	$421.5K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.960M	$4.608M
Total Long-Term Assets	$421.5K	$0.00
Total Assets	$2.382M	$4.608M
YoY Change	-61.03%	-85.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$296.2K	$138.7K
YoY Change	-5.99%	-58.83%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$4.181M
YoY Change		20.05%
Long-Term Debt Due		$17.50K
YoY Change
Total Short-Term Liabilities	$11.62M	$4.651M
YoY Change	193.07%	21.77%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$19.58K
YoY Change		-91.31%
Total Long-Term Liabilities	$705.3K	$422.4K
YoY Change	6528.57%	87.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.62M	$4.651M
Total Long-Term Liabilities	$705.3K	$422.4K
Total Liabilities	$12.33M	$4.671M
YoY Change	210.03%	15.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.94M	-$8.550M
YoY Change	476.14%	9.06%
Common Stock	$1.390K	$3.880M
YoY Change	-99.96%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.947M	-$4.669M
YoY Change
Total Liabilities & Shareholders Equity	$2.382M	$4.608M
YoY Change	-61.03%	-85.26%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$8.928M	-$126.1K
YoY Change	-8446.27%	-78.22%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$738.0K	-$121.0K
YoY Change	843.13%	-14.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	$130.1K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$746.2K	132.0K
YoY Change	-102.98%	-101.3%
NET CHANGE
Cash From Operating Activities	-$738.0K	-121.0K
Cash From Investing Activities	$130.1K	0.000
Cash From Financing Activities	$746.2K	132.0K
Net Change In Cash	$171.8K	11.05K
YoY Change	-100.68%	-99.96%
FREE CASH FLOW
Cash From Operating Activities	-$738.0K	-$121.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther		usd
	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1914079	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39341
	dei	Entity Registrant Name EntityRegistrantName	BRILLIANT ACQUISITION CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Floor 20-21
	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 55 Loushanguan Road
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Changning District
	dei	Entity Address City Or Town EntityAddressCityOrTown	Shanghai
	dei	Entity Address Country EntityAddressCountry	CN
	dei	City Area Code CityAreaCode	(86)
	dei	Local Phone Number LocalPhoneNumber	021-80125497
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1814696	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4608097	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6110807	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	738	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	4608097	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6111545	usd
CY2023Q3	us-gaap	Assets Assets	4608097	usd
CY2022Q4	us-gaap	Assets Assets	6111545	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	470007	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	315023	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4651434	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3965850	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	19577	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10643	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4671011	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3976493	usd
CY2023Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	403696	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	564936	shares
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4606578	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6055016	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	3880288	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3880288	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8549780	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7800252	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4669492	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3919964	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4608097	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6111545	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	116668	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	480867	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	459994	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1094728	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-116668	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-480867	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-459994	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1094728	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9394	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	106184	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8934	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	44801	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	8298	usd
	us-gaap	Interest Income Other InterestIncomeOther	64950	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9394	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-97886	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8934	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20149	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-126062	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-578753	usd
	us-gaap	Net Income Loss NetIncomeLoss	-468928	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1074579	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1914079	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4539123	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1926145	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5342708	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-4446530	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-126062	usd
CY2023Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-96900	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4669492	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3919964	usd
	us-gaap	Net Income Loss NetIncomeLoss	-468928	usd
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-280600	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4669492	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3019078	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-578753	usd
CY2022Q3	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-353000	usd
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	8298	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3959129	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1832006	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1074579	usd
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-987594	usd
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	64950	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3959129	usd
	us-gaap	Net Income Loss NetIncomeLoss	-468928	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1074579	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8934	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	44801	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-738	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51976	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	154984	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	27245	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-304272	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1054509	usd
	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	47387687	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	47387687	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	250000	usd
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	987594	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	280600	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	870100	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	1729038	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	17272165	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1198438	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15414471	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1502710	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	30918707	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6110807	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283403	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4608097	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31202110	usd
	brli	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	280600	usd
	brli	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	1052544	usd
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2020Q2	brli	Gross Proceed GrossProceed	6210000	usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2020Q2	us-gaap	Cash Reserve Deposit Required And Made CashReserveDepositRequiredAndMade	6000000	usd
	brli	Trust Account Amount TrustAccountAmount	46000000	usd
	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2069154	usd
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1610000	usd
	brli	Other Offering Cost OtherOfferingCost	459154	usd
CY2023Q3	us-gaap	Investments And Cash InvestmentsAndCash	1520	usd
CY2023Q3	brli	Fair Market Value Percentage FairMarketValuePercentage	0.80	pure
CY2023Q3	brli	Additional Price Per Share AdditionalPricePerShare	0.08
CY2021Q2	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2021Q3	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	633792	shares
CY2022Q1	brli	Aggregate Amounts AggregateAmounts	6529259	usd
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.3
CY2022Q1	us-gaap	Deposit Assets DepositAssets	101406	usd
CY2022Q1	brli	Aggregate Amount Shares AggregateAmountShares	633792	shares
CY2022Q3	brli	Aggregate Amount Shares AggregateAmountShares	1025281	shares
CY2022Q3	brli	Aggregate Amounts AggregateAmounts	10742906	usd
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.48
CY2022Q4	brli	Public Ordinary Per Share PublicOrdinaryPerShare	0.04
CY2022Q4	brli	Aggregate Amount Shares AggregateAmountShares	2375991	shares
CY2022Q4	brli	Aggregate Amounts AggregateAmounts	25180851	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.6
CY2022Q4	us-gaap	Deposit Assets DepositAssets	22600	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.04
CY2022Q4	us-gaap	Deposit Assets DepositAssets	22600	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.04
	brli	Ordinary Price Per Share OrdinaryPricePerShare	0.04
	brli	Description Of Deposite DescriptionOfDeposite	Trust Account for any extension from February 23, 2023 to March 23, 2023 and from March 23, 2023 to April 23, 2023 to $0.08 per ordinary share outstanding. In connection with the extension, Nukkleus deposited $21,350 into the Trust Account, representing $0.0525 per public ordinary share that was not redeemed in connection with extending the business combination completion window until February 23, 2023. In connection with a special meeting to approve the extension of the business combination period, the Company’s shareholders elected to redeem an aggregate amount of 159,203 shares, and the Company redeemed such shares for an aggregate amount of $1,706,347, or approximately $10.72 per share.
CY2023Q1	us-gaap	Deposit Assets DepositAssets	32500	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q2	brli	Public Per Share PublicPerShare	0.08
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
	brli	Aggregate Amount Shares AggregateAmountShares	258	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2821	usd
CY2023Q3	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q3	us-gaap	Deposit Assets DepositAssets	32300	usd
	brli	Aggregate Amount Of Shares AggregateAmountOfShares	1779	shares
	brli	Aggregate Amounts AggregateAmounts	19870	usd
	brli	Aggregate Price Per Share AggregatePricePerShare	11.17
CY2023Q3	us-gaap	Deposit Assets DepositAssets	32300	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q3	us-gaap	Deposit Assets DepositAssets	32300	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q4	us-gaap	Deposit Assets DepositAssets	32300	usd
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
	brli	Redeemption Percent RedeemptionPercent	1	pure
	us-gaap	Other Expenses OtherExpenses	50000	usd
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1520	usd
CY2023Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	1689087	usd
	us-gaap	Trustee Fees TrusteeFees	32300	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3	brli	Cash And Noncash Equivalents CashAndNoncashEquivalents	1520	usd
CY2022Q4	brli	Cash And Noncash Equivalents CashAndNoncashEquivalents	55789	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	633792	shares
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1025281	shares
CY2022Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2375991	shares
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	159203	shares
CY2023Q2	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	258	shares
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1779	shares
CY2023Q3	brli	Subject To Possible Redemption SubjectToPossibleRedemption	403696	shares
CY2022Q4	brli	Subject To Possible Redemption SubjectToPossibleRedemption	564936	shares
	brli	Common Stock Per Share CommonStockPerShare	10
CY2021Q4	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	47387687	usd
CY2022	brli	Redemption Of Share RedemptionOfShare	633792	shares
CY2022	brli	Less Redemption Of Shares LessRedemptionOfShares	6529259	shares
CY2022	brli	Redemption Of Share1 RedemptionOfShare1	1025281	shares
CY2022	brli	Less Redemption Of Shares1 LessRedemptionOfShares1	10742905	shares
CY2022	brli	Redemption Of Share2 RedemptionOfShare2	2375991	shares
CY2022	brli	Less Redemption Of Shares2 LessRedemptionOfShares2	-25180851	shares
CY2022	brli	Add Accretion Of Carrying Value To Redemption Value AddAccretionOfCarryingValueToRedemptionValue	-64950	shares
CY2022	brli	Reclassification Of Temporary Equity ReclassificationOfTemporaryEquity	1055394	shares
CY2022Q4	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	6055016	usd
	brli	Redemption Of Share3 RedemptionOfShare3	159203	shares
	brli	Less Redemption Of Shares3 LessRedemptionOfShares3	-1706347	shares
	brli	Redemption Of Shares4 RedemptionOfShares4	258	shares
	brli	Less Redemption Of Shares4 LessRedemptionOfShares4	-2821	shares
	brli	Redemption Of Shares5 RedemptionOfShares5	1779	shares
	brli	Less Redemption Of Shares6 LessRedemptionOfShares6	-19870	shares
	brli	Reclassifications Of Temporary To Permanent Equity1 ReclassificationsOfTemporaryToPermanentEquity1	280600	shares
CY2023Q3	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	4606578	usd
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-126062	usd
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-578753	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-468928	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1074579	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1914079	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4539123	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1926145	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5342708	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
	brli	Business Combination BusinessCombination	P1Y
	brli	Ordinary Exceeds Per Share OrdinaryExceedsPerShare	12.5
	brli	Public Per Share Outstanding PublicPerShareOutstanding	0.04
CY2021Q4	brli	Trust Account Management Expense TrustAccountManagementExpense	1000	usd
CY2022Q1	brli	Trust Account Management Expense TrustAccountManagementExpense	500	usd
CY2022Q1	brli	Aggregate Of Shares AggregateOfShares	633792	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2821	usd
CY2023Q3	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32450	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32450	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32300	usd
CY2023Q3	us-gaap	Deposits Deposits	0.08	usd
	brli	Aggregate Of Shares AggregateOfShares	1779	shares
CY2023Q3	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	19870	usd
	brli	Aggregate Per Share AggregatePerShare	11.17
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32300	usd
CY2022	us-gaap	Preferred Stock Shares Authorized Unlimited PreferredStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32300	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32300	usd
	brli	Working Capital WorkingCapital	1220600	usd
	us-gaap	Direct Operating Costs DirectOperatingCosts	250000	usd
	brli	Aggregate Amount AggregateAmount	1610000	usd
CY2023Q3	brli	Cash Fee Equal Percentage CashFeeEqualPercentage	0.01	pure
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2023Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	403696	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	564936	shares
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.01
	brli	Class Of Warrant Or Right Redemption Of Warrants Or Rights Stock Price ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPrice	16.5
	brli	Description Of Warrants For Redemption DescriptionOfWarrantsForRedemption	In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	261000	shares
	us-gaap	Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1	8934	usd
	us-gaap	Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1	44801	usd
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.0348	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.034	pure
CY2023Q3	us-gaap	Share Price SharePrice	11.62
CY2022Q4	us-gaap	Share Price SharePrice	10.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y25D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M23D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0457	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0404	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	180479	usd
CY2022Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	5041	usd
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	175438	usd
CY2022Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	56342	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	119096	usd
CY2022Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-106184	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	225280	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10643	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-925	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	11568	usd
CY2023Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	1385	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	10183	usd
CY2023Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-9394	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	19577	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2023Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
	us-gaap	Preferred Stock Shares Authorized Unlimited PreferredStockSharesAuthorizedUnlimited	Unlimited
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1926144	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4539123	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	brli	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount		usd
	brli	Interest Earned On Marketable Securities Held In Trust Account InterestEarnedOnMarketableSecuritiesHeldInTrustAccount		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1914079	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1926144	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4539123	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5342708	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities		usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	000000
	dei	Entity Central Index Key EntityCentralIndexKey	0001787518

Files In Submission

Name	View Source	Status
0001213900-23-088733-index-headers.html	Edgar Link	pending
0001213900-23-088733-index.html	Edgar Link	pending
0001213900-23-088733.txt	Edgar Link	pending
0001213900-23-088733-xbrl.zip	Edgar Link	pending
brli-20230930.xsd	Edgar Link	pending
brli-20230930_cal.xml	Edgar Link	unprocessable
f10q0923ex31-1_brilliant.htm	Edgar Link	pending
f10q0923ex31-2_brilliant.htm	Edgar Link	pending
f10q0923ex32-1_brilliant.htm	Edgar Link	pending
f10q0923_brilliant.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brli-20230930_def.xml	Edgar Link	unprocessable
brli-20230930_lab.xml	Edgar Link	unprocessable
brli-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_brilliant_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NUKK
Nukkleus Inc. Stock $nukk

2023 Q4 Form 10-Q Financial Statement

#000121390023088733 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUKK Nukkleus Inc. Stock $nukk

2023 Q4 Form 10-Q Financial Statement

#000121390023088733 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUKK
Nukkleus Inc. Stock $nukk